Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.

Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR.

J Natl Cancer Inst. 2012 Sep 5;104(17):1320-34. doi: 10.1093/jnci/djs336. Epub 2012 Aug 21.

2.

Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy.

Brennen WN, Isaacs JT, Denmeade SR.

Mol Cancer Ther. 2012 Feb;11(2):257-66. doi: 10.1158/1535-7163.MCT-11-0340. Review.

3.

Fibroblast activation protein: A potential therapeutic target in cancer.

Liu R, Li H, Liu L, Yu J, Ren X.

Cancer Biol Ther. 2012 Feb 1;13(3):123-9. doi: 10.4161/cbt.13.3.18696. Epub 2012 Feb 1. Review.

PMID:
22236832
4.

Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy.

Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD.

Proteomics Clin Appl. 2014 Jun;8(5-6):454-63. doi: 10.1002/prca.201300095. Epub 2014 Mar 24. Review.

PMID:
24470260
5.

Fibroblast activation protein in remodeling tissues.

Jacob M, Chang L, Puré E.

Curr Mol Med. 2012 Dec;12(10):1220-43. Review.

PMID:
22834826
6.

Targeted prodrug approaches for hormone refractory prostate cancer.

Aloysius H, Hu L.

Med Res Rev. 2015 May;35(3):554-85. doi: 10.1002/med.21333. Epub 2014 Dec 22. Review.

PMID:
25529338
8.

Fibroblast activation protein-α: a key modulator of the microenvironment in multiple pathologies.

Kelly T, Huang Y, Simms AE, Mazur A.

Int Rev Cell Mol Biol. 2012;297:83-116. doi: 10.1016/B978-0-12-394308-8.00003-0. Review.

PMID:
22608558
9.

Targeting thapsigargin towards tumors.

Doan NT, Paulsen ES, Sehgal P, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Dionne CA, Christensen SB.

Steroids. 2015 May;97:2-7. doi: 10.1016/j.steroids.2014.07.009. Epub 2014 Jul 24. Review.

10.

DPIV/CD26 and FAP in cancer: a tale of contradictions.

Sulda ML, Abbott CA, Hildebrandt M.

Adv Exp Med Biol. 2006;575:197-206. Review. No abstract available.

PMID:
16700523
11.

Imaging aspects of the tumor stroma with therapeutic implications.

Narunsky L, Oren R, Bochner F, Neeman M.

Pharmacol Ther. 2014 Feb;141(2):192-208. doi: 10.1016/j.pharmthera.2013.10.003. Epub 2013 Oct 14. Review.

12.

Tumour endoproteases: the cutting edge of cancer drug delivery?

Atkinson JM, Siller CS, Gill JH.

Br J Pharmacol. 2008 Apr;153(7):1344-52. doi: 10.1038/sj.bjp.0707657. Epub 2008 Jan 21. Review.

13.

Tumor-activated prodrugs--a new approach to cancer therapy.

Denny WA.

Cancer Invest. 2004;22(4):604-19. Review.

PMID:
15565818
14.

The application of the fibroblast activation protein α-targeted immunotherapy strategy.

Jiang GM, Xu W, Du J, Zhang KS, Zhang QG, Wang XW, Liu ZG, Liu SQ, Xie WY, Liu HF, Liu JS, Wu BP.

Oncotarget. 2016 May 31;7(22):33472-82. doi: 10.18632/oncotarget.8098. Review.

15.

Prodrug applications for targeted cancer therapy.

Giang I, Boland EL, Poon GM.

AAPS J. 2014 Sep;16(5):899-913. doi: 10.1208/s12248-014-9638-z. Epub 2014 Jul 9. Review.

16.

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.

Phillips RM.

Cancer Chemother Pharmacol. 2016 Mar;77(3):441-57. doi: 10.1007/s00280-015-2920-7. Epub 2016 Jan 25. Review.

17.

Prodrugs for improving tumor targetability and efficiency.

Mahato R, Tai W, Cheng K.

Adv Drug Deliv Rev. 2011 Jul 18;63(8):659-70. doi: 10.1016/j.addr.2011.02.002. Epub 2011 Feb 17. Review.

18.

The tumor microenvironment: a target for combination therapy of breast cancer.

Reisfeld RA.

Crit Rev Oncog. 2013;18(1-2):115-33. Review.

PMID:
23237555
19.

Proteases in cancer drug delivery.

Vandooren J, Opdenakker G, Loadman PM, Edwards DR.

Adv Drug Deliv Rev. 2016 Feb 1;97:144-55. doi: 10.1016/j.addr.2015.12.020. Epub 2016 Jan 3. Review.

PMID:
26756735
20.

Nuclear structure as a source of cancer specific biomarkers.

Leman ES, Getzenberg RH.

J Cell Biochem. 2008 Aug 15;104(6):1988-93. Review.

Supplemental Content

Support Center